Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZAUBT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
wO2024222841A1 ADC39-4
|
|||||
| Synonyms |
ADC39-4
Click to Show/Hide
|
|||||
| Organization |
CSPC MEGALITH BIOPHARMACEUTICAL CO.,LTD.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
(S)B19
|
Payload Info | ||||
| Therapeutic Target |
Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)
|
Target Info | ||||
| Linker Name |
OXD-VA-PAB (PEG)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
LD39
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 15-25 pM | High HER2 expression (HER2+++) | ||
| Method Description |
Cytotoxicity of ADC to SK-BR-3 cells
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||